In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.

    Keith Flaherty, MD
    Cancer Commons Advisor

  • Dr. Rahib is extremely helpful and I am very thankful to have access to such professional and state-of-the-art support.

    Ines
    Daughter of pancreatic cancer patient

  • The team at Cancer Commons provided options above and beyond what the local care team had offered. Such a great service for patients.

    Anonymous

  • Sincere thanks to Cancer Commons and their Virtual Tumor Board for their comprehensive analysis and recommendations regarding treatments for my pancreatic cancer. I feel fortunate to have the benefit of the expertise offered by their board of scientists, researchers, physicians, and experts in this field.

    Roy Saenz

  • I appreciated the quick response after my registration with Cancer Commons. The nurse navigator was prompt and compassionate. I knew my request wasn’t going to be buried and didn’t have time to wonder how long it would take before I got a response. The scientist Lauren connected me too was very prompt in giving me answers to my question. And when I asked questions... Read more »

    Gail Lung cancer patient

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.